March 2016 PMID 26272051

5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder.

Pedro E Martinez, David R Rubinow, Lynnette K Nieman, Deloris E Koziol, A Leslie Morrow, Crystal E Schiller, Dahima Cintron, Karla D Thompson, Khursheed K Khine, Peter J Schmidt

Download social card

Mentions

Peak: 2 in Oct 2021

across 3 sources since Oct 2021

Extended reach

118,425

potential audience

Total likes

2,322

Video views

104,291

Mentions per month

Oct 2021 – Sep 2024

Where it's discussed

News8 articles
YouTube4 videos
X / Twitter3 posts

AI synopsis

What people are saying

Overall, the discussion reflects limited depth, with users showing mild interest by mentioning related substances like saw palmetto and posing simple questions. The tone is casual and dismissive, focusing on superficial associations rather than in-depth analysis or impact, which aligns with the neutral scoring across all dimensions.

AgreementNeither agree nor disagree

The discussion shows minimal direct support or opposition to the study, with one poster mentioning a related medication and others mostly echoing interest without firm stances.

InterestNeutral interest

Participants demonstrate slight curiosity, primarily through mentions of related substances like saw palmetto and questions about the content, but overall engagement with the study is limited.

EngagementNeutral engagement

The posts are brief and lack detailed analysis, with one user referencing a common supplement and others sharing personal reactions or questions, indicating shallow engagement.

ImpactNeutral impact

The conversation seems confined to basic awareness; there's no indication that these posts reflect or contribute to broader influence or significant changes in understanding.

Abstract in brief

Researchers investigated how neurosteroid levels impact symptoms of premenstrual dysphoric disorder (PMDD) by using the drug dutasteride to stabilize these levels in women.
The study included 32 women (16 with PMDD and 16 control) over three menstrual cycles, comparing the effects of dutasteride to a placebo in a controlled setting.
Results showed that while low doses of dutasteride had no significant effect on PMDD symptoms, higher doses led to a notable reduction in irritability, sadness, and anxiety among women with PMDD, with no mood changes in control women.

Read the full abstract